Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study).
Yamashita T, Ikeda T, Akita Y.
J Cardiol. 2019 May;73(5):386-393. doi: 10.1016/j.jjcc.2018.11.009.

EFFECT OF HYDROPHILIC AND HYDROPHOBIC POLYMER ON IN VITRO DISSOLUTION AND PERMEATION OF BISOPROLOL FUMARATE THROUGH TRANSDERMAL PATCH.
Shabbir M, Ali S, Raza M, Sharif A, Akhtar FM, Manan A, Fazli AR, Younas N, Manzoor I.
Acta Pol Pharm. 2017 Jan;74(1):187-197.

Head-to-head comparison of the heart rate variability between the bisoprolol transdermal patch and bisoprolol fumarate tablet.
Sairaku A, Nakano Y, Shiode N, Suenari K, Oda N, Ono K, Kihara Y.
Cardiovasc Ther. 2018 Jun;36(3):e12325. doi: 10.1111/1755-5922.12325.

Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure.
Momomura SI, Saito Y, Yasumura Y, Yamamoto K, Sakata Y, Daimon M, Kinugawa K, Okamoto H, Dohi N, Komuro I.
Circ J. 2017 Dec 25;82(1):141-147. doi: 10.1253/circj.CJ-17-0532.

IN VITRO TESTING OF XANTHAN/LIGNIN HYDROGELS AS CARRIERS FOR CONTROLLED DELIVERY OF BISOPROLOL FUMARATE.
Răschip IE, Panainte AD, Pamfil D, Profire L, Vasile C.
Rev Med Chir Soc Med Nat Iasi. 2015 Oct-Dec;119(4):1189-94.

Preparation of bisoprolol fumarate nasal spray and its nasal delivery in rats.
Fugen G, Duo H, Gendalai M, Chunzhi W, Yi W.
Pak J Pharm Sci. 2015 Nov;28(6):2173-8.

Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study.
Matsuoka H, Kuwajima I, Shimada K, Mitamura H, Saruta T.
J Clin Hypertens (Greenwich). 2013 Nov;15(11):806-14. doi: 10.1111/jch.12208.

Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
Hori M, Nagai R, Izumi T, Matsuzaki M.
Heart Vessels. 2014 Mar;29(2):238-47. doi: 10.1007/s00380-013-0340-3.

 Bisoprolol fumarate, a derivative of phenoxy-2-propanol, is a drug widely used to treat chronic heart failure in transdermal, tablet form.

It is a beta-blocker also used in the treatment of hypertension, atrial fibrillation, postural tachycardia syndrome, angina and arrhythmia.

Antihypertensive drugs in the form of transdermal patches in particular are considered clinically significant as they allow stable control of diastolic pressure (1).

It exerts an antioxidant activity and, due to its lipophilic nature, facilitates the passage in the brain tissue to produce therapeutic actions on central neurons (2).

In a comparison, the tolerability, effectiveness and safety of bisoprolol and carvedilol do not show significant differences (3).

Like all drugs it can cause side effects. Always consult your doctor.

Bisoprolol fumarate studies

Molecular Formula: C₂₂H₃₅NO₈

Molecular  Weight: 441.5 g/mol

CAS: 105878-43-1  104344-23-2

EC Number: 600-557-5

MDL number MFCD00792743

PubChem Substance ID 24724414

Synonyms:

• Bisoprololum
• Bisoprolol monofumarate
• Cardicor
• Bisocor
• Detensiel
• Emconcor
• Euradal
• Soloc
• Monocor
• Emcor
• Isoten
• Soprol
• 1-(4-((2-Isopropoxyethoxy)methyl)phenoxy)-3-(isopropylamino)propan-2-ol hemifumarate
• (E)-but-2-enedioic acid; 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol
• 1-(4-((2-isopropoxyethoxy)methyl)phenoxy)-3-(isopropylamino)propan-2-ol fumarate
• 1-[4-[[2-(1-Methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol hemifumarate salt

References________________________________________________________________________

(1) EFFECT OF HYDROPHILIC AND HYDROPHOBIC POLYMER ON IN VITRO DISSOLUTION AND PERMEATION OF BISOPROLOL FUMARATE THROUGH TRANSDERMAL PATCH.  Shabbir M, Ali S, Raza M, Sharif A, Akhtar FM, Manan A, Fazli AR, Younas N, Manzoor I.  Acta Pol Pharm. 2017 Jan;74(1):187-197.

(2) Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples.  Sigaroudi A, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F.  Pharmacology. 2018;101(1-2):29-34. doi: 10.1159/000480091.

(3) Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction　- The CIBIS-J Trial.  Tsutsui H, Momomura SI, Masuyama T, Saito Y, Komuro I, Murohara T, Kinugawa S; CIBIS-J Investigators.  Circ J. 2019 May 24;83(6):1269-1277. doi: 10.1253/circj.CJ-18-1199.